scholarly journals Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
E. C. Inwald ◽  
O. Ortmann ◽  
F. Zeman ◽  
M. Koller ◽  
F. Hofstädter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Large Population ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%,P=0.006versus 79%,P=0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab

Breast Cancer ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 292-299 ◽  
Author(s):  
Junichi Kurebayashi ◽  
Naoki Kanomata ◽  
Tetsumasa Yamashita ◽  
Toshiro Shimo ◽  
Akiko Mizutoh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Outcome of HER2-positive breast cancer patients following metastatic relapse after adjuvant trastuzumab treatment since EMA regulatory approval.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 641-641 ◽  
Author(s):  
Jean-Philippe Spano ◽  
Stéphane Vignot ◽  
Xuan Dung Ho ◽  
Nayi Zongo ◽  
Celine Magneux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Breast Cancer Patients ◽  
Time To Progression ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Metastatic Relapse ◽  
Positive Breast Cancer

641 Background: Trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2) is approved in France since 2005 for HER2-positive breast cancer patients in the adjuvant setting. Efficacy of this treatment is clearly established but little is known related to patient outcome if they develop metastatic relapse after adjuvant trastuzumab. The aim of this study is to analyse these relapses with a special focus on efficacy of anti-HER2 treatment in this setting. Methods: We analysed 456 patients with HER2-positive early breast cancer treated with trastuzumab containing adjuvant therapy between 2006 and 2011 in two Departments of Medical Oncology from Université Pierre et Marie Curie, Paris, France. Data from patients with metastatic relapse were identified. Disease free survival (DFS) between end of trastuzumab and relapse, quality of response, and time to progression after anti-HER2 new treatment are reported. Results: Relapse rate was 3.3 % after adjuvant trastuzumab (15 pts, median age 53 years, ER+ 40 %). DFS between end of trastuzumab and relapse was 244 days (95% CI: 91 - 397 days). One pt actually had a confirmed HER2-negative metastatic disease. The other 14 pts were treated with anti-HER2 agents at relapse. On 12 evaluable pts, an objective response was observed in 8 pts, stabilisation in 2 pts and progression in 2 pts. Median time to progression after first line metastatic treatment was 222 days (95% CI: 114 - 330 days). Additional data about site of relapse and subsequent therapies are available. Conclusions: Relapse after adjuvant trastuzumab remains a rare event in this real life cohort of breast cancer pts. For these pts, we will present data of the patterns of relapse and response. These data may help us to determine if adjuvant trastuzumab has an impact on outcome of HER2 metastatic disease compared to data in trastuzumab naive metastatic HER2-positive breast cancer pts. We also plan to seek international collaboration to expand our analyses, as well as overall survival.

Sign in / Sign up

Export Citation Format

Share Document